US 12,405,274 B2
Methods for the detection and treatment of lung cancer
Samir Hanash, Houston, TX (US); Ayumu Taguchi, Houston, TX (US); and Ziding Feng, Houston, TX (US)
Assigned to Board of Regents, The University of Texas System, Houston, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Mar. 28, 2023, as Appl. No. 18/191,506.
Application 18/191,506 is a division of application No. 16/484,177, previously published as PCT/US2018/017704, filed on Feb. 9, 2018.
Claims priority of provisional application 62/456,731, filed on Feb. 9, 2017.
Prior Publication US 2023/0314436 A1, Oct. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/574 (2006.01); G16B 5/20 (2019.01)
CPC G01N 33/57423 (2013.01) [G01N 33/57484 (2013.01); G16B 5/20 (2019.02)] 5 Claims
OG exemplary drawing
 
1. A method comprising
(a) obtaining a biological sample from a subject;
(b) measuring levels of biomarkers in the sample, wherein the biomarkers comprise CEA, CA125, CYFRA21-1, and PRO-SFTPB;
(c) combining the measured levels into a biomarker-based risk score, wherein the biomarker-based risk score is calculated using logistic regression analysis;
(d) quantifying an increased risk for the presence of lung cancer in the subject by matching the biomarker-based risk score to a risk category of a grouping of stratified subject populations, wherein each risk category comprises a multiplier indicating increased likelihood of having lung cancer correlated to a range of composite scores as compared to use of a single threshold value;
(e) classifying the subject as lung-cancer positive based on the increased risk of having lung cancer quantified in step (d); and
(f) administering to the lung-cancer positive subject a therapeutically effective amount of a treatment for the lung cancer comprising surgery, chemotherapy, immunotherapy, radiation therapy, targeted therapy, or a combination thereof.